Syon Capital LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Syon Capital LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 782 shares of the biopharmaceutical company’s stock after purchasing an additional 168 shares during the period. Syon Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $687,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Meyer Handelman Co. increased its position in Regeneron Pharmaceuticals by 11.4% during the third quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after buying an additional 435 shares in the last quarter. Stifel Financial Corp increased its position in Regeneron Pharmaceuticals by 12.2% during the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after buying an additional 3,385 shares in the last quarter. LPL Financial LLC increased its position in Regeneron Pharmaceuticals by 9.3% during the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock worth $33,522,000 after buying an additional 3,479 shares in the last quarter. Cavalier Investments LLC increased its position in Regeneron Pharmaceuticals by 88.6% during the third quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company’s stock worth $3,651,000 after buying an additional 2,084 shares in the last quarter. Finally, Exchange Traded Concepts LLC increased its position in Regeneron Pharmaceuticals by 32.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after buying an additional 1,221 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,325,338. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the transaction, the director now owns 18,382 shares in the company, valued at $17,540,472.04. The disclosure for this sale can be found here. Insiders have sold 11,022 shares of company stock valued at $10,552,991 in the last quarter. Corporate insiders own 8.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on REGN. Truist Financial restated a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. Barclays lifted their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. UBS Group lifted their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Finally, BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $977.77.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $7.48 during mid-day trading on Friday, hitting $883.20. The company had a trading volume of 504,289 shares, compared to its average volume of 491,044. The stock has a market cap of $96.94 billion, a price-to-earnings ratio of 25.63, a PEG ratio of 2.60 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The firm’s 50 day simple moving average is $949.30 and its two-hundred day simple moving average is $893.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business’s revenue was up .6% on a year-over-year basis. During the same quarter last year, the business posted $10.96 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.